. Author manuscript; available in PMC: 2018 Feb 6.

Published in final edited form as: J Biopharm Stat. 2017 Feb 6;27(3):477–494. doi: 10.1080/10543406.2017.1289952

Table 4.

Case Study 2: Probability of selecting each dose as the maximum tolerated dose (MTD). Results for the true MTD are in bold.

	Dose 1	Dose 2	Dose^* 3
Assumed DLT probabilities used in simulations	0	0.20	0.40
‘3+3’ design (N = 11)^**	0.29	0.48	0.23
TITE-CRM (N = 22)	0.07	0.80	0.13
TITE-CRM (N = 12)	0.14	0.70	0.16

MTD declared by the end of the original trial was later deemed unsafe due to late onset toxicities.

^**

Average sample size obtained from 2,000 simulated trials.

TITE-CRM: Time-o-event Continual Reassessment Method.